Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Keros Therapeutics Q4 EPS $(1.34) Beats $(1.37) Estimate

Author: Happy Mohamed | February 28, 2024 05:33pm
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(1.37) by 2.19 percent. This is a 22.94 percent decrease over losses of $(1.09) per share from the same period last year.

Posted In: KROS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist